Loading...
SPRC logo

SciSparc Ltd.NasdaqCM:SPRC Stock Report

Market Cap US$2.6m
Share Price
n/a
1Y-88.0%
7D-4.0%
1D0.9%
Portfolio Value
​
View

SciSparc Ltd.

NasdaqCM:SPRC Stock Report

Market Cap: US$2.6m

SciSparc (SPRC) Stock Overview

A clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. More details

SPRC fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($856K)

Earnings have declined by 13.3% per year over past 5 years

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

+ 1 more risk

SPRC Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW434,055 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
434,055 investors already sharing narratives
View all narratives

SciSparc Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for SciSparc
Historical stock prices
Current Share PriceUS$4.57
52 Week HighUS$80.10
52 Week LowUS$2.98
Beta2.44
1 Month Change-31.74%
3 Month Change-22.08%
1 Year Change-88.00%
3 Year Change-99.40%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Aug 15

SciSparc to acquire an American food supplements and cosmetics brand in ~$20M deal

A specialty clinical-stage pharmaceutical company SciSparc (NASDAQ:SPRC) signed a letter of intent with Merhavit M.R.M Holding and Management to acquire from it its rights to purchase, a top-seller Amazon.com account and American food supplements and cosmetics brand and trademark (Brand). The Brand offers dozens of GMP (Good Manufacturing Practice) manufactured hemp-based, U.S. made, top-ranked products, including various food supplements for different purposes and cosmetics. Company will pay a base payment of $4.59M upon closing of the transaction and an additional deferred cash payment of up to $1.1M that will be based on a multiple of 12 months EBITDA of the acquired Brand. “Our decision to enter this LOI is part of a previous board of directors decision to search for strategic transactions in high growth, high potential markets. We believe that acquiring a profitable top-seller brand with millions of dollars in annual sales, combined with our knowledge and expertise, can provide value to our shareholders. This potential transaction will expand our access to manufacturing and distribution channels, which aligns with our intention to market CannaMideTM, our PEA- based food supplement.“ commented Oz Adler, CEO.
Seeking Alpha • Jul 06

SciSparc board of directors to promote buyback program of up to $1M

SciSparc (NASDAQ:SPRC) authorized the company to take actions to implement a $1M buyback program for the company’s ordinary shares. The company expects to formally approve the buyback in conjunction with the approval of its financial statements for the 6 months ended June 30, 2022, together with a financial advisor’s opinion to be obtained.
Seeking Alpha • Jun 29

SciSparc completes development of SCI-110 to treat tourette syndrome

SciSparc (NASDAQ:SPRC) said on Wednesday it completed the development of its drug candidate, SCI-110, for Phase IIb study to treat tourette syndrome. SCI-110 is developed and manufactured by Procaps Group S.A. Tourette syndrome is a movement and neurobehavioral disorder characterized by chronic motor and vocal tics. The main goal of the study is to assess tic severity change as a continuous endpoint at week 12 and week 26.

Shareholder Returns

SPRCUS PharmaceuticalsUS Market
7D-4.0%1.4%1.8%
1Y-88.0%49.6%13.3%

Return vs Industry: SPRC underperformed the US Pharmaceuticals industry which returned 49.6% over the past year.

Return vs Market: SPRC underperformed the US Market which returned 13.3% over the past year.

Price Volatility

Is SPRC's price volatile compared to industry and market?
SPRC volatility
SPRC Average Weekly Movement24.7%
Pharmaceuticals Industry Average Movement8.3%
Market Average Movement6.8%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market2.8%

Stable Share Price: SPRC's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SPRC's weekly volatility has decreased from 30% to 25% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20043Oz Adlerscisparc.com

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others.

SciSparc Ltd. Fundamentals Summary

How do SciSparc's earnings and revenue compare to its market cap?
SPRC fundamental statistics
Market capUS$2.63m
Earnings (TTM)-US$12.18m
Revenue (TTM)US$856.00k
3.1x
P/S Ratio
-0.2x
P/E Ratio

Is SPRC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SPRC income statement (TTM)
RevenueUS$856.00k
Cost of RevenueUS$225.00k
Gross ProfitUS$631.00k
Other ExpensesUS$12.81m
Earnings-US$12.18m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-20.96
Gross Margin73.72%
Net Profit Margin-1,422.78%
Debt/Equity Ratio6.9%

How did SPRC perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/22 22:35
End of Day Share Price 2026/09/22 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SciSparc Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation
Piriyapon KongvanichBualuang Securities PCL
Maxim JacobsEdison Investment Research